T he phospholipid platelet-activating factor (PAF) stimulates a single receptor (PAFR) expressed by platelets, but also by nearly every other cell of the innate immune system, and by numerous cells of the cardiovascular system. PAF and its receptor regulate inflammation, atherogenesis, cardiac rhythm, liver contractility, body temperature, and vascular tone. [1] [2] [3] [4] PAF is remarkably potent, activating cells at concentrations of 10 Ϫ12 mol/L, 5 suggesting its presence is tightly controlled. However, its blood concentration can increase, for instance after ischemic stroke 6 and inflammatory stress. 7 A single enzyme in blood metabolizes PAF 8, 9 and bioactive 10 oxidatively modified phospholipids 11 that accumulate in atherosclerosis 12 and in response to other oxidative insults. 13 Common names for this lipoprotein-associated enzyme are plasma PAF acetylhydrolase (PAF-AH) or lipoprotein-associated phospholipase (Lp-PL)A 2 , but its gene name is group VII phospholipase A 2 (PLA2G7). PAF as a relatively soluble phospholipid is bound to lipoproteins, mainly albumin, 14 with rapid exchange from lipoprotein particles 15 allowing access both to PLA2G7 and the PAF receptor.
There is significant controversy whether PLA2G7 is protective or promotes chronic inflammation, cardiovascular disease and atherogenesis, 16 and direct manipulation of this activity in humans has not clarified the issue. A phase III trial administering recombinant human plasma PAF acetylhydrolase to septic patients did not decrease mortality. 17 Conversely, chronic suppression of circulating enzymatic activity with the experimental drug Darapladib did not reduce circulating oxidized phospholipids nor alter human plaque volume. 18 Still, plasma PAF acetylhydrolase is a strong and independent risk factor for cardiovascular disease, 19 and a large (Ϸ15 000 individuals) phase III trial is underway to determine whether Lp-PLA 2 inhibition reduces incidence of first occurrence of major adverse cardiovascular events.
The focus on PAF-AH/Lp-PLA 2 in controlling the amounts of circulating PAF or oxidized phospholipids has yet to incorporate the results of a single early report indicating that PAF is rapidly cleared from rat circulation by transport into tissues. 20 Whether this uptake process is slower or faster than PLA2G7 action on PAF or oxidized phospholipids in plasma has not been examined, nor is it known whether transport of PAF and short-chain lipids occurs in species other than rat.
Here, we show that PAF is cleared from murine circulation in seconds as an intact molecule through saturable uptake by endothelium. This disappearance was faster than PAF hydrolysis in human or murine blood, and ablation of PLA2G7 had no immediate effect on PAF clearance. The implications are that transport rather than intravascular hydrolysis primarily controls circulating PAF levels; that PAF and oxidized phospholipids are continually, and rapidly, released to the circulation to achieve steady state levels; that an excess of oxidized phospholipids promotes inflammation by competitively slowing PAF clearance; and, that PAF catabolism primarily occurs in the intracellular compartment of tissues, reducing the role for circulating, although perhaps not intracellular, PLA2G7 in in vivo PAF catabolism.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
In Vivo Phospholipid Metabolism
[ 3 H-acetyl]PAF in 0.5% albumin in PBS, with or without a 1,000-molar excess of inactive enantiomeric PAF or a 2000-fold excess of synthetic AzPC, was injected into the retroorbital plexus.
Phospholipid Mass Spectrometry
Mass spectrometric analyses were performed on-line using electrospray ionization tandem mass spectrometry in the positive ion mode with multiple reaction monitoring using the molecular cation [MH] ϩ and the m/z 184 daughter phosphocholine ion.
Immunohistochemistry
Fluorescent NBD-PAF or NBD-AzLPAF were introduced by retroorbital injection. Organs were recovered 5 minutes later after extensively flushing the vasculature with PBS. Organs were excised, immediately frozen in liquid nitrogen, and embedded in OTC media for sectioning.
Statistics
The data represent the meansϮSD of the stated number of samples. The statistical analyses used a paired Student t test. For all of these hypotheses, the significance level was 0.05.
Results

PAF Disappeared From Circulation Faster Than Hydrolysis in Plasma
The half life of [ 3 H-acetyl]PAF in human plasma was Ϸ7 minutes ( Figure 1A ), as we previously observed. 23 We also observed that the turnover of [ 3 H-acetyl]PAF was somewhat quicker in plasma than in whole blood where some 40% of plasma volume is displaced by blood cell volume. A similar pattern of efficient hydrolysis of [ 3 H]PAF in plasma relative to blood held when murine material was examined ( Figure  1A) Figure 1B ). We were technically unable to perform more blood collections over these short times to better define the precise t 1/2 , but it is apparent that the turnover in vivo is far faster than in ex vivo blood samples.
In Vivo PAF Clearance Was Independent of the PAF Receptor PAF internalization by murine macrophages is a function of the PAF receptor, 24 Plasma PLA2G7 (PAF-AH/ Lp-PLA 2 ) is the sole enzyme in blood to effectively degrade PAF, 26 and a global PLA2G7 knockout has now been found to sensitize animals to necrotizing enterocolitis. 27 [ 3 H]PAF clearance in PLA2G7 Ϫ/Ϫ mice was not different over the first minute when Ϸ75% of the label was cleared ( Figure 1D ). After this time, however, turnover was significantly delayed by loss of this enzyme.
Tissue Uptake and Intracellular PAF Catabolism
PAF that rapidly disappeared from the circulation might be internalized by tissues as the intact phospholipid and then rapidly metabolized as it enters, might be fully recovered from one or more of these organs as the intact phospholipid, or may be distributed between these 2 outcomes. We collected the major organs 5 minutes after [ 3 H-acetyl]PAF injection, a time when vascular PAF had been fully cleared. We first extensively perfused the animals with buffer to remove residual blood-borne label before harvesting the organs. Most soft tissues accumulated intact [ 3 H]PAF, with liver and lung accounting for the bulk of this accumulation ( Figure 2A ). In part, preferential accumulation of [ 3 H]PAF by liver reflected organ size, and when accumulation was normalized by wet weight it is apparent that [ 3 H]PAF was preferentially accumulated by lung and spleen ( Figure 2B ). These data show PAF was accumulated by least some organs as the intact phospholipid because the solvent extraction separates this lipid from its aqueous Figure 2C ) where only Ϸ3% of the label remained as the intact phospholipid 5 minutes postinjection (compare 2A with 2C). Similarly, only Ϸ7% of the label remained as PAF in kidney, whereas lung retained nearly half its label as intact PAF. This pattern is congruent with the abundance of type II PAF acetylhydrolase (an intracellular enzyme with 41% identity to PLA2G7 with a similar substrate preference) in liverϭkidneyϾ Ͼlung. 11
Vascular Endothelium Accumulated Vascular PAF
We sought to identify where intravascular PAF accumulated in the soft organs by introducing NBD-labeled PAF by the retroorbital route and collecting the organs 5 minutes later after exsanguination and buffer perfusion as before. We found sections of lung, liver and kidney fluoresced brightly in this experiment, heart less so, and brain not at all ( Figure 3A ). We also found clearly delineated patches of bright fluorescence in spleen. The accumulated fluorescence marks intact PAF, and its NBD-lysoPAF and NBD-phosphatidylcholine metabolites, because the NBD label in the lysoPAF backbone is in the nonhydrolyzable sn-1 alkyl residue. Thin layer chromatography confirmed (not shown) fluorescence was confined to these complex phospholipids and had not been converted to a neutral lipid.
Immunohistochemical detection of endothelial CD31 indicated that fluorescent PAF and its phospholipid metabolites primarily accumulated in endothelium ( Figure  3B ). The large vessel adjacent to an unstained bronchiole shows strong colocalization of fluorescent PAF and CD31 (an endothelial cell and platelet specific marker), but also that the phospholipid had been released into the subluminal compartment. Similarly, endothelium of a large renal vessel was strongly positive for the NBD label, as were numerous smaller vessels. The strongly punctate staining Ϫ/Ϫ mice (nϭ5) and wild-type BL6 mice (nϭ3) was assessed on the same day as above.
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of spleen was revealed to reflect the distribution of white pulp vessels with little staining away from the vessels (not shown).
A Short-Chain Phospholipid Competed for In Vivo PAF Clearance
We wished to determine whether clearance of trace quantities of [ 3 H]PAF was saturable, and so would be slowed by high PAF concentrations. We cannot test this in vivo with PAF because of its strong vasoactivity, but the stereoisomer of PAF, although chemically identical, is not recognized by the PAF receptor 28 and is not vasoactive. We observed that a 1000-fold molar excess of the enantiomeric stereoisomer of PAF reduced the rate of clearance of [ 3 H]PAF as the t 1/2 increased from less than 30 seconds to Ϸ3 minutes ( Figure  4A , left).
An Oxidatively Truncated Phospholipid and PAF Shared a Clearance Mechanism
PAF is a short-chain phospholipid (the sn-2 residue is a 2-carbon acetyl residue) and oxidatively truncated phospholipids with short sn-2 residues accumulate in the circulation in response to hyperlipidemia 12 or oxidative stress, 13 which might slow PAF clearance through competition. We repeated the in vivo [
3 H]PAF clearance experiments in the presence of a large molar excess of chemically synthesized Az-lysoPAF, an abundant proapoptotic oxidatively truncated phospholipid. 29 Excess Az-lysoPAF also significantly reduced the rate of clearance of intravascular [ 3 H-acetyl]PAF ( Figure 4A , right). We next injected fluorescent Az-lysoPAF to determine whether this oxidatively truncated phospholipid was internalized, and whether this was by the same type of cells that acquired circulating PAF, to find that it also accumulated in endothelium and subendothelial structures ( Figure 4B ).
We determined whether isolated liver tissue was able to accumulate extracellular PAF using precision-cut liver slices. In this approach, liver was sectioned into 1000-m-thick slices with a Krumdieck Tissue Slicer that maintain organ ultrastructure while allowing cellular access to extracellular materials. Incubation of precision cut liver slices with NBD- Fluorescent NBD-labeled PAF (10 g in 100 L of PBS containing 0.5% human serum albumin) was injected, or nothing, into 10-week-old wild-type male mice through the retroorbital plexus as before. The mice were extensively perfused with PBS 5 minutes after injection, and organs were extracted in sequence and frozen immediately. The tissue was OTC-embedded, sectioned, and stained for endothelial cell CD31, and fluorescent micrographs were captured at ϫ4 magnification. B, Endothelium and PAF costaining. NBD-PAF-labeled sections (top, lung; middle, kidney; lower, spleen) were stained, or not (right), with anti-CD31 and Alexa647-conjugated secondary antibody before fluorescent micrographs (ϫ63 magnification) were generated by confocal laser scanning microscopy.
PAF for 1 minute showed this fluorescent phospholipid was rapidly accumulated by liver cells (Figure 4C ), particularly in areas around the central vein. Inclusion of a 100-fold molar excess of PAF (here using biologically active PAF) greatly reduced fluorescent PAF uptake. The oxidatively truncated phospholipid Az-lysoPAF was similarly effective in reducing fluorescent PAF uptake. Both PAF and an oxidatively truncated phospholipid thus appear to compete for PAF uptake ex vivo in a structurally intact tissue.
Short-Chain Choline Phospholipid and PAF Import Share TMEM30a
Phospholipid import is undefined in mammals, but genetic approaches in Saccharomyces cerevisiae show choline phospholipid uptake requires Lem3/DRS1 or DRS2 heterodimers. 30 Humans express TMEM30 mRNA whose sequence is similar to Lem3, but unknown protein function. We find phospholipid uptake is reconstituted by human TMEM30a or human TMEM30a/yeast Lem3 chimeras in Lem3 deletion mutants, and TMEM30a knockdown reduces PAF uptake by CHO and Jurkat cells. 30a We found that human endothelial cells also express mRNA encoding TMEM30a, and that small interfering (si)RNA to this sequence reduced its mRNA compared to cognate scrambled RNA ( Figure 5A ). siRNA knockdown of TMEM30a also reduced uptake of fluorescent NBD-labeled phosphatidylcholine compared to cells transfected with scrambled RNA ( Figure 5B ) in a quantitatively significant way ( Figure 5C ). Endothelial cells internalize fluorescent BODIPY-labeled PAF ( Figure 5D, top) , which was suppressed in the presence Ϫ6 mol/L) enantiomeric PAF (3-O-hexadecyl-2-acetyl-sn-glycero-1-phosphocholine) in 0.5% human serum albumin in PBS. Enantiomeric PAF is chemically identical to PAF, but the PAF receptor is not activated by this stereoisomer and so blood pressure and the inflammatory response are not altered as they would be in response to micromolar PAF. Blood samples were collected at the stated times and processed to quantitate [ 3 H-acetyl]PAF as in Figure 1 .
Right, Trace quantity of [
3 H]PAF (10 Ci) was mixed with excess (2ϫ10 Ϫ6 mol/L) synthetic Az-lysoPAF, and [ 3 H]PAF clearance was measured as before. B, Lung endothelium accumulates circulating Az-lysoPAF. NBD-labeled Az-lysoPAF was injected, animals were perfused with PBS 5 minutes later, and organs were harvested and processed and costained with anti-CD31 as in Figure 3B . C, Short-chain phospholipids compete for labeled PAF uptake in precision-cut liver slices. Freshly isolated mouse liver was sectioned into 1000-m-thick sections with a Krumdieck Tissue Slicer. The liver slices were treated for 1 minute with 100 ng/mL fluorescent NBD-PAF in the absence (a) or presence (10 g/mL) of unlabeled PAF (b), or Az-lysoPAF (c). The treated slices were placed in 2 mL of PBS containing 5% human serum albumin, washed 3 times, immediately frozen in liquid nitrogen, and then embedded in OTC. Sections were examined by fluorescence microscopy, and micrographs were captured at ϫ10 magnification. 
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[ 3 H]PAF Clearance Was Decreased in ApoE
؊/؊
Mice With Enhanced Intravascular Levels of Short-Chain Phospholipids
A bolus of short-chain phospholipids slowed [ 3 H]PAF clearance in vivo, and a series of such short-chain phospholipids circulates in hyperlipidemic apolipoprotein (apo)E Ϫ/Ϫ animals. 12 We found PAF and Az-PC concentrations also were higher in the circulation of apoE Ϫ/Ϫ animals fed a high-fat diet for 6 weeks compared to wild type animals on this diet ( Figure 6A ). We injected trace amounts of [ 3 H]PAF into animals maintained on the high-fat diet for 6 weeks to determine whether endogenous short-chained phospholipids slowed PAF clearance. Indeed, [ 3 H-acetyl]PAF disappeared significantly more slowly from the circulation of apoE Ϫ/Ϫ mice than BL6 control animals ( Figure 6B ). We examined the tissue distribution of [ 3 H]PAF in apoE Ϫ/Ϫ and wild-type animals on a high-fat diet to determine whether uptake into all organs was uniformly altered. The data show all tissues of apoE Ϫ/Ϫ animals, except brain where significance was not attained, accumulated [ 3 H]PAF more slowly than their wild-type counterparts ( Figure 6C ).
Discussion
PLA2G7 is the sole enzyme in plasma to appreciably catabolize PAF and short-chain phospholipid oxidation products. This is established by mutations in Japanese and other Asian populations where plasma from homozygous individuals who lack this enzyme cannot hydrolyze PAF, whereas plasma from heterozygous individuals hydrolyze PAF at half the rate of individuals with 2 wild-type alleles. 31, 32 Despite this, individuals with reduced levels of PLA2G7 activity do not display rampant inflammatory responses anticipated from uncontrolled PAF accumulation, 33, 34 nor does acute bronchoconstriction to inhaled PAF vary in these individuals. 35 Additionally, a recent meta-analysis of Ϸ26,000 individuals revealed PLA2G7 variants, such as 379V, were associated with modest changes in enzymatic activity, but were not associated with cardiovascular risk markers, coronary atheroma, or coronary heart disease. 36 Here, we find that circulating PLA2G7 is not the only way PAF is cleared from blood. [ 3 H]PAF clearance initially occurred through tissue uptake by a system using TMEM30a that accepts choline phospholipids as transport substrates. Ϫ/Ϫ mice on a high-fat diet. Plasma was isolated from wild-type and apoE Ϫ/Ϫ mice (nϭ5) after 6 weeks on a high-fat diet, deuterated d 4 -PAF was added as an internal standard, and phospholipids were extracted 21 and purified over an HyperSep NH 2 cartridge before reverse-phase highperformance liquid chromatographic separation and analysis by electrospray ionization tandem mass spectrometry. C 16:0 -PAF was separated from isobaric lysophosphatidylcholine by normalphase chromatography before reversephase chromatography. B, We propose that circulating PAF and phospholipid oxidation products accumulate in the inflammatory apoE Ϫ/Ϫ hyperlipidemic model because saturable transport limits their clearance. In hyperlipidemia, a plethora of short-chain phospholipid oxidation products are available to compete and slow transport of PAF and the other biologically active phospholipids. In this way, hyperlipidemia can promote inflammation. Our studies were conducted in mice, where the PLA2G7 activity is 8.6 times that of humans, 43 suggesting hydrolysis in human circulation would be even less effective, although human PAF turnover is yet to be investigated.
PAF was primarily transported as the intact molecule because a significant portion of PAF and Az-LPAF were recovered from tissue as intact molecules, particularly in lung. Additionally, intact PAF was recovered well after it would have been hydrolyzed had it remained in the circulation. By example, 3 minutes postinjection when Ϸ98% of intravascular PAF had been cleared from the circulation, only about half of this could have been hydrolyzed in plasma by this time.
In contrast, the majority of PAF was hydrolyzed in liver and kidney after internalization, and both hepatocytes and renal cells abundantly express type II intracellular PAF acetylhydrolase that also specifically hydrolyzes PAF. 2, 4 Liver Kupffer cells, as differentiated tissue macrophages, additionally retain a portion of the PLA2G7 they make, 44 so intracellular PLA2G7 may contribute to intracellular PAF metabolism.
Uptake of intact PAF can have a biological consequence because the PAF receptor is present in intracellular compartments, 45 and the PAF receptor of isolated nuclei stimulates a Ca 2ϩ flux and initiates inflammatory gene transcription. 46 These observations indicate intracellular PAF receptors in cells lacking robust hydrolytic activity have the potential to respond to extracellular PAF.
PAF is cleared from the circulation with great rapidity, so the presence of PAF in blood 47 requires equally rapid secretion to counterbalance turnover. The concentration of circulating PAF increases with inflammatory or pathological insults, 7, 13, 48 indicating either or both increased production and release in response to these insults. Pathways contributing to circulating PAF remain opaque, but likely include the combination of reduced PLA2G7 hydrolytic activity, 49 increased intracellular PAF synthesis, 50 and, at least in yeast, export facilitated by P-glycoprotein ABC transporters. 51 Circulating PAF may be the product of mononuclear cells because of all the cells known to synthesize PAF, only monocytes release PAF. 52, 53 Reduced phospholipid uptake might also enhance circulating PAF concentrations, but molecular details of this internalization process are just now being defined. Uptake of PAF and a related structure edelfosine (PAF with an alkyl sn-2 residue) by genetically tractable yeast requires a heterodimeric complex of the P4-type ATPase DRS1 or DRS2, 54 and lem3 (also discovered as ros3). 55 Mutational analysis of the corresponding human ATPase homolog ATP8B1 shows it has no role in phospholipid import, 56 but we find TMEM30a, a human lem3p homolog, reconstitutes phospholipid import in S cerevisiae and aids PAF uptake by cell lines. 30a The finding here that TMEM30a is expressed by endothelial cells and facilitates phospholipid import suggest that the rapid clearance of circulating PAF reflects transport into endothelial cell rich organs including lung, liver, and kidney.
What New Information Does This Article Contribute?
• Circulating PAF is primarily controlled by transport, not intravascular hydrolysis.
• PAF is cleared from murine circulation with a t 1/2 of Ϸ30 seconds.
• PAF and oxidized phospholipids rapidly enter the circulation to maintain steady-state levels.
• PAF and oxidized phospholipids compete for uptake, and hyperlipidemia slows PAF clearance.
PAF activates vascular and innate immune cells at subpicomolar concentrations, so its presence in circulation must be tightly controlled. A single plasma enzyme encoded by PLA2G7 hydrolyzes PAF and oxidatively truncated phospholipids in plaque and hyperlipidemic plasma, and its loss in Asian populations prevents PAF hydrolysis in blood. However, this population is not at risk for cardiovascular disease, nor was disease enhanced in subjects testing Darapladib that inhibits this enzyme. We found PAF is primarily cleared from murine circulation by transport, not intravascular hydrolysis. Uptake was rapid (t 1/2 , Ϸ30 seconds) and independent of the PAF receptor. Endothelial cell uptake of PAF and an antitumor phospholipid was aided by TMEM30a, a homolog of a yeast phosphatidylcholine transporter. PAF and a truncated phospholipid compete for uptake, so hyperlipidemia slowed clearance. PAF was transported as an intact phospholipid, and then rapidly hydrolyzed in liver, the primary recipient organ, and kidney, which express significant levels of PAF acetylhydrolase activity. 
